 |
NEW YORK, July 10, 2025 /PRNewswire/ -- YPO, the global leadership community of chief executives in more than 150 countries, proudly announces the appointment of Debby Carreau as Global Chairman of the YPO Board of Directors, the organization's highest elected office.
Carreau officially began her one-year term on 1 July 2025, becoming the 74th member to hold this prestigious role. She succeeds YPO Chairman Emeritus Sofyan Almoayed.
"It is an honor to serve as YPO's global chairman and to give back to a community that has profoundly shaped my leadership journey," Carreau said. "As we celebrate YPO's 75th anniversary, I'm inspired by the bold new ideas and connections that continue to define this extraordinary organization. Together, we'll focus on shaping the future of leadership, by amplifying innovation, connection and purpose across our global community."
A member of the YPO Gold British Columbia and YPO Alberta Gold chapters, Carreau is the CEO and founder of Inspired HR, a human resources consultancy that supports over 300,000 employees across diverse industries. She also recently launched Stack HRo. Recognized as one of Canada's Most Powerful Women, Carreau is a respected human capital thought leader, serving on numerous corporate and nonprofit boards. She is also the author of The Mentor Myth, a guide to building meaningful careers through self-driven development.
Carreau joined YPO in 2011 and has held a variety of leadership positions, including deputy chairman, chair of the Global Conduct Committee, chair of the Compensation and HR Committee, and global board director from 2019–2023. She has also championed member experience across chapter, regional and network roles.
Over the course of her chairmanship, Carreau will focus on elevating new ideas as a driving force for leadership development and global connection. Now more than ever, in a rapidly shifting world, she seeks to empower leaders who can meet challenges head-on and lead their businesses and communities with clarity, courage and global vision. She will also pivot YPO toward its next 75 years of growth, relevance and global impact.
About YPO
YPO is the global leadership community of more than 35,000 chief executives in 150 countries who are driven by the shared belief that the world needs better leaders. Each of our members has achieved significant leadership success at a young age and is part of the YPO community throughout their life and career, driven by a commitment to lifelong learning and impact. Collectively, YPO members lead businesses and organizations contributing more than USD9 trillion in annual revenue and employ more than 22 million people globally. To learn more, visit ypo.org.
NEW YORK, July 10, 2025 /PRNewswire/ -- YPO, the global leadership community of chief executives in more than 150 countries, proudly announces the appointment of Debby Carreau as Global Chairman of the YPO Board of Directors, the organization's highest elected office.
Carreau officially began her one-year term on 1 July 2025, becoming the 74th member to hold this prestigious role. She succeeds YPO Chairman Emeritus Sofyan Almoayed.
"It is an honor to serve as YPO's global chairman and to give back to a community that has profoundly shaped my leadership journey," Carreau said. "As we celebrate YPO's 75th anniversary, I'm inspired by the bold new ideas and connections that continue to define this extraordinary organization. Together, we'll focus on shaping the future of leadership, by amplifying innovation, connection and purpose across our global community."
A member of the YPO Gold British Columbia and YPO Alberta Gold chapters, Carreau is the CEO and founder of Inspired HR, a human resources consultancy that supports over 300,000 employees across diverse industries. She also recently launched Stack HRo. Recognized as one of Canada's Most Powerful Women, Carreau is a respected human capital thought leader, serving on numerous corporate and nonprofit boards. She is also the author of The Mentor Myth, a guide to building meaningful careers through self-driven development.
Carreau joined YPO in 2011 and has held a variety of leadership positions, including deputy chairman, chair of the Global Conduct Committee, chair of the Compensation and HR Committee, and global board director from 2019–2023. She has also championed member experience across chapter, regional and network roles.
Over the course of her chairmanship, Carreau will focus on elevating new ideas as a driving force for leadership development and global connection. Now more than ever, in a rapidly shifting world, she seeks to empower leaders who can meet challenges head-on and lead their businesses and communities with clarity, courage and global vision. She will also pivot YPO toward its next 75 years of growth, relevance and global impact.
About YPO
YPO is the global leadership community of more than 35,000 chief executives in 150 countries who are driven by the shared belief that the world needs better leaders. Each of our members has achieved significant leadership success at a young age and is part of the YPO community throughout their life and career, driven by a commitment to lifelong learning and impact. Collectively, YPO members lead businesses and organizations contributing more than USD9 trillion in annual revenue and employ more than 22 million people globally. To learn more, visit ypo.org.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
YPO Elects Debby Carreau 2025-2026 Global Chairman
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
